Back to results
US 2011/0236402 A1Published application
Enhancement of light activated therapy by immune augmentation using anti-ctla-4 antibody
AssigneeLight Sciences Oncology, Inc.
InventorJames C. Chen
Life of this patent
Estimating the term…
Abstract
The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced.
Claims8
A method for destroying cancerous tissue within a patient's body, comprising the steps of:
- (a) administering a light activated drug therapy treatment to the treatment site, the light activated drug therapy treatment destroying a portion of the cancerous tissue at the treatment site and releasing factors that stimulate the patient's immune system;
- and
- (b) administering an immune system stimulating factor to the patient in association with the light activated drug therapy treatment, said immune system stimulating factor and said light activated drug therapy together having a synergistic effect that systemically enhances destruction of cancerous tissue, even to cancerous tissue that itself has not been treated by the light activated drug therapy treatment, the immune system stimulating factor comprising an anti-CTLA-4 antibody, release of the factors that stimulate the patient's immune system caused by the light activated drug therapy enabling a lower dose of the anti-CTLA-4 antibody to be used than is normally used when administered without also administering the light activated drug therapy.
Dependencies are inferred from the claim text.